Sign in
Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors
Journal article   Peer reviewed

Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors

Theodore C Jessop, James E Tarver, Marianne Carlsen, Amy Xu, Jason P Healy, Alexander Heim-Riether, Qinghong Fu, Jerry A Taylor, David J Augeri, Min Shen, …
Bioorganic & medicinal chemistry letters, Vol.19(23), pp.6784-6787
2009
PMID: 19836232

Abstract

Deoxycytidine kinase Cancer Immunology Pharmacokinetics Virology
A series of deoxycytidine kinase inhibitors was simultaneously optimized for potency and PK properties. A co-crystal structure then allowed merging this series with a high throughput screening hit to afford a highly potent, selective and orally bioavailable inhibitor, compound 10. This compound showed dose dependent inhibition of deoxycytidine kinase in vivo.

Details